Population-based Analysis of Invasive Fungal Infections, France, 2001-2010

Overview

Journal Emerg Infect Dis

Specialty Infectious Diseases

Date 2014 Jun 25

PMID 24960557

Citations 159

Authors

Dounia Bitar

Olivier Lortholary

Yann Le Strat

Javier Nicolau

Bruno Coignard

Pierre Tattevin

Didier Che

Francoise Dromer

Affiliations

Soon will be listed here.

Abstract

To determine the epidemiology and trends of invasive fungal infections (IFIs) in France, we analyzed incidence, risk factors, and in-hospital death rates related to the most frequent IFIs registered in the national hospital discharge database during 2001-2010. The identified 35,876 IFI cases included candidemia (43.4%), Pneumocystis jirovecii pneumonia (26.1%), invasive aspergillosis (IA, 23.9%), cryptococcosis (5.2%), and mucormycosis (1.5%). The overall incidence was 5.9/100,000 cases/year and the mortality rate was 27.6%; both increased over the period (+1.5%, +2.9%/year, respectively). Incidences substantially increased for candidemia, IA, and mucormycosis. Pneumocystis jirovecii pneumonia incidence decreased among AIDS patients (-14.3%/year) but increased in non-HIV-infected patients (+13.3%/year). Candidemia and IA incidence was increased among patients with hematologic malignancies (>+4%/year) and those with chronic renal failure (>+10%/year). In-hospital deaths substantially increased in some groups, e.g., in those with hematologic malignancies. IFIs occur among a broad spectrum of non-HIV-infected patients and should be a major public health priority.

Citing Articles

Species-Specific Sensitivity and Levels of Beta-D-Glucan for the Diagnosis of Candidemia-A Systematic Review and Meta-Analysis.

Ullah N, Muccio M, Magnasco L, Sepulcri C, Giacobbe D, Vena A J Fungi (Basel). 2025; 11(2).

PMID: 39997443 PMC: 11856011. DOI: 10.3390/jof11020149.

Acute Necrotizing Fasciitis Caused by Infection in a Patient with Diabetes and Pulmonary Tuberculosis: A Case Report.

Huang X, Qiu J, Pan L, Wang C, Tang C Infect Drug Resist. 2025; 18:775-782.

PMID: 39958980 PMC: 11827498. DOI: 10.2147/IDR.S503791.

Review of the novel antifungal drug olorofim (F901318).

Vanbiervliet Y, Nieuwenhuyse T, Aerts R, Lagrou K, Spriet I, Maertens J BMC Infect Dis. 2024; 24(1):1256.

PMID: 39511507 PMC: 11542455. DOI: 10.1186/s12879-024-10143-3.

The emerging links between immunosenescence in innate immune system and neurocryptococcosis.

Soraci L, Beccacece A, Princiotto M, Villalta Savedra E, Gambuzza M, Aguennouz M Front Immunol. 2024; 15:1410090.

PMID: 39229268 PMC: 11369721. DOI: 10.3389/fimmu.2024.1410090.

Epidemiology and prognostic factors of mucormycosis in France (2012-2022): a cross-sectional study nested in a prospective surveillance programme.

Gouzien L, Che D, Cassaing S, Lortholary O, Letscher-Bru V, Paccoud O Lancet Reg Health Eur. 2024; 45:101010.

PMID: 39220434 PMC: 11363841. DOI: 10.1016/j.lanepe.2024.101010.

References

Chang D, Burwell L, Lyon G, Pappas P, Chiller T, Wannemuehler K . Comparison of the use of administrative data and an active system for surveillance of invasive aspergillosis . Infect Control Hosp Epidemiol. 2008; 29(1):25-30. DOI: 10.1086/524324. View

Sandven P, Bevanger L, Digranes A, Haukland H, Mannsaker T, Gaustad P . Candidemia in Norway (1991 to 2003): results from a nationwide study. J Clin Microbiol. 2006; 44(6):1977-81. PMC: 1489391. DOI: 10.1128/JCM.00029-06. View

Dromer F, Mathoulin-Pelissier S, Launay O, Lortholary O . Determinants of disease presentation and outcome during cryptococcosis: the CryptoA/D study. PLoS Med. 2007; 4(2):e21. PMC: 1808080. DOI: 10.1371/journal.pmed.0040021. View

Bitar D, Van Cauteren D, Lanternier F, Dannaoui E, Che D, Dromer F . Increasing incidence of zygomycosis (mucormycosis), France, 1997-2006. Emerg Infect Dis. 2009; 15(9):1395-401. PMC: 2819884. DOI: 10.3201/eid1509.090334. View

Kainer M, Reagan D, Nguyen D, Wiese A, Wise M, Ward J . Fungal infections associated with contaminated methylprednisolone in Tennessee. N Engl J Med. 2012; 367(23):2194-203. PMC: 4669562. DOI: 10.1056/NEJMoa1212972. View

Lanternier F, Dannaoui E, Morizot G, Elie C, Garcia-Hermoso D, Huerre M . A global analysis of mucormycosis in France: the RetroZygo Study (2005-2007). Clin Infect Dis. 2012; 54 Suppl 1:S35-43. DOI: 10.1093/cid/cir880. View

Maini R, Henderson K, Sheridan E, Lamagni T, Nichols G, Delpech V . Increasing Pneumocystis pneumonia, England, UK, 2000-2010. Emerg Infect Dis. 2013; 19(3):386-92. PMC: 3647665. DOI: 10.3201/eid1903.121151. View

Menzin J, Meyers J, Friedman M, Korn J, Perfect J, Langston A . The economic costs to United States hospitals of invasive fungal infections in transplant patients. Am J Infect Control. 2010; 39(4):e15-20. DOI: 10.1016/j.ajic.2010.06.009. View

Brown G, Denning D, Levitz S . Tackling human fungal infections. Science. 2012; 336(6082):647. DOI: 10.1126/science.1222236. View

10.

Kontoyiannis D, Marr K, Park B, Alexander B, Anaissie E, Walsh T . Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis. 2010; 50(8):1091-100. DOI: 10.1086/651263. View

11.

Asmundsdottir L, Erlendsdottir H, Gottfredsson M . Increasing incidence of candidemia: results from a 20-year nationwide study in Iceland. J Clin Microbiol. 2002; 40(9):3489-92. PMC: 130691. DOI: 10.1128/JCM.40.9.3489-3492.2002. View

12.

Zilberberg M, Shorr A, Kollef M . Secular trends in candidemia-related hospitalization in the United States, 2000-2005. Infect Control Hosp Epidemiol. 2008; 29(10):978-80. DOI: 10.1086/591033. View

13.

Bitar D, Morizot G, Van Cauteren D, Dannaoui E, Lanternier F, Lortholary O . Estimating the burden of mucormycosis infections in France (2005-2007) through a capture-recapture method on laboratory and administrative data. Rev Epidemiol Sante Publique. 2012; 60(5):383-7. DOI: 10.1016/j.respe.2012.03.007. View

14.

Fanfair R, Benedict K, Bos J, Bennett S, Lo Y, Adebanjo T . Necrotizing cutaneous mucormycosis after a tornado in Joplin, Missouri, in 2011. N Engl J Med. 2012; 367(23):2214-25. DOI: 10.1056/NEJMoa1204781. View

15.

Al-Shair K, Atherton G, Harris C, Ratcliffe L, Newton P, Denning D . Long-term antifungal treatment improves health status in patients with chronic pulmonary aspergillosis: a longitudinal analysis. Clin Infect Dis. 2013; 57(6):828-35. PMC: 3749749. DOI: 10.1093/cid/cit411. View

16.

Lamagni T, Evans B, Shigematsu M, Johnson E . Emerging trends in the epidemiology of invasive mycoses in England and Wales (1990-9). Epidemiol Infect. 2001; 126(3):397-414. PMC: 2869708. DOI: 10.1017/s0950268801005507. View

17.

Dromer F, Mathoulin-Pelissier S, Fontanet A, Ronin O, Dupont B, Lortholary O . Epidemiology of HIV-associated cryptococcosis in France (1985-2001): comparison of the pre- and post-HAART eras. AIDS. 2004; 18(3):555-62. DOI: 10.1097/00002030-200402200-00024. View

18.

Rees J, Pinner R, Hajjeh R, Brandt M, Reingold A . The epidemiological features of invasive mycotic infections in the San Francisco Bay area, 1992-1993: results of population-based laboratory active surveillance. Clin Infect Dis. 1998; 27(5):1138-47. View

19.

Laupland K, Gregson D, Church D, Ross T, Elsayed S . Invasive Candida species infections: a 5 year population-based assessment. J Antimicrob Chemother. 2005; 56(3):532-7. DOI: 10.1093/jac/dki258. View

20.

Azie N, Neofytos D, Pfaller M, Meier-Kriesche H, Quan S, Horn D . The PATH (Prospective Antifungal Therapy) Alliance® registry and invasive fungal infections: update 2012. Diagn Microbiol Infect Dis. 2012; 73(4):293-300. DOI: 10.1016/j.diagmicrobio.2012.06.012. View